Table 4.
Recipient Characteristics.
| Characteristic | G-CSF | PEG-G-CSF | P |
|---|---|---|---|
| Number | 42 | 83 | |
| Patient age, median(range) | 30 (8, 55) | 29 (10, 62) | .782 |
| Patient gender, male/female, n | 23/19 | 51/32 | .473 |
| Diagnosis | .445 | ||
| AML/high-risk MDS, n | 21 | 34 | |
| ALL, n | 6 | 23 | |
| NHL/ANKL/CAEBV, n | 7 | 10 | |
| CML/CMML, n | 2 | 2 | |
| SAA, n | 6 | 14 | |
| Donor age, median(range) | 34.5 (8, 59) | 32 (13, 56) | .280 |
| Donor gender, male/female, n | 31/11 | 61/22 | .970 |
| Donor type, n | <.001 | ||
| Matched sibling donor | 19 | 21 | |
| Mismatched related donor | 14 | 62 | |
| Matched unrelated donor | 9 | 0 | |
| Donor-recipient sex match, n | .662 | ||
| Male–male | 18 | 36 | |
| Male–female | 13 | 25 | |
| Female–male | 5 | 15 | |
| Female–female | 6 | 7 | |
| Donor–recipient relation, n | <.001 | ||
| Sibling–sibling | 24 | 39 | |
| Parent–child | 9 | 27 | |
| Child–parent | 0 | 17 | |
| Others | 9 | 0 | |
| ABO matched, n | .261 | ||
| Matched | 25 | 44 | |
| Major mismatched | 8 | 19 | |
| Minor mismatched | 4 | 16 | |
| Bidirect mismatched | 5 | 4 | |
| Disease status at HSCT, n* | .910 | ||
| CR | 27 | 55 | |
| PR | 6 | 13 | |
| Conditioning regimen, n | .759 | ||
| Bu-Cy-based regimen | 31 | 56 | |
| TBI-Cy-based regimen | 5 | 13 | |
| Flu-Cy-ATG regimen | 6 | 14 | |
| GVHD prophylaxis, n | .008 | ||
| CsA+MTX | 23 | 22 | |
| CsA+MTX+MMF | 14 | 46 | |
| FK506+MTX+MMF | 5 | 15 |
*: n = 101, which did not include SAA and CAEBV.
HSCT, hematopoietic stem cell transplantation; CsA, cyclosporin A; MTX, methotrexate; MMF, mycophenolate mofetil.